Theriva Biologics Inc.
$ 0.26
1.94%
17 Apr - close price
- Market Cap 11,803,600 USD
- Current Price $ 0.26
- High / Low $ 0.26 / 0.25
- Stock P/E N/A
- Book Value 0.43
- EPS -2.08
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -1.38 %
- 52 Week High 1.50
- 52 Week Low 0.16
About
Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$2.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-12 | 2025-11-12 | 2025-08-11 | 2025-05-05 | 2025-03-24 | 2024-11-11 | 2024-08-13 | 2024-05-07 | 2024-03-25 | 2023-11-13 | 2023-08-08 | 2023-05-11 |
| Reported EPS | -0.0982 | -0.45 | -1.93 | -1.55 | -11.49 | -6.8107 | -10.75 | -0.3 | -0.34 | -0.19 | -0.34 | -0.3 |
| Estimated EPS | -0.37 | -1.13 | -1.08 | -1.56 | -7.22 | -5.25 | -0.28 | -0.34 | -0.41 | -0.37 | -0.36 | -0.32 |
| Surprise | 0.2718 | 0.68 | -0.85 | 0.01 | -4.27 | -1.5607 | -10.47 | 0.04 | 0.07 | 0.18 | 0.02 | 0.02 |
| Surprise Percentage | 73.4595% | 60.177% | -78.7037% | 0.641% | -59.1413% | -29.7276% | -3739.2857% | 11.7647% | 17.0732% | 48.6486% | 5.5556% | 6.25% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TOVX
2026-04-18 16:40:04
Theriva Biologics announced positive data from its VIRAGE Phase 2b clinical trial of VCN-01 in combination with chemotherapy for newly diagnosed metastatic pancreatic cancer (mPDAC), presented at AACR 2026. The data show improved outcomes and prolonged survival, especially in patients with liver metastases, suggesting an immune-mediated mechanism. The company has also aligned with the FDA and EMA on a pivotal Phase 3 trial design, reducing regulatory risks for VCN-01.
2026-04-17 21:39:25
Theriva Biologics saw a significant post-market surge of 67.92%, making it a trending stock. The article focuses on recent stock movements and highlights the notable performance of this particular biotech company.
2026-04-17 21:39:25
Theriva Biologics announced positive data from its VIRAGE Phase 2b clinical trial for VCN-01 in metastatic pancreatic cancer, showing improved overall survival and progression-free survival when combined with chemotherapy. These findings suggest an immune-mediated mechanism and support plans for a pivotal Phase 3 program. Despite the positive clinical data, TipRanks' AI Analyst, Spark, rates TOVX as Neutral due to financial performance concerns and financing risk.
2026-04-17 20:39:25
Theriva Biologics, Inc. (TOVX) filed an 8-K report detailing an upcoming presentation at the AACR 2026 Annual Meeting. The company will share new data from its VIRAGE Phase 2b trial of VCN-01 combined with gemcitabine/nab-paclitaxel for metastatic pancreatic cancer. Key findings suggest improved overall and progression-free survival, with an immune-mediated mode of action, and the company has aligned with the FDA and EMA for a pivotal Phase 3 trial.
2026-04-17 19:39:25
Theriva™ Biologics will present new data and subgroup analyses from its VIRAGE Phase 2b clinical trial evaluating VCN-01 in metastatic pancreatic cancer at the AACR 2026 Annual Meeting. The data, including tumor response and biomarker analyses, support an immune-mediated mode of action for VCN-01 and show improved outcomes across various patient subgroups. The company also announced alignment with the FDA and EMA for a proposed pivotal Phase 3 clinical trial and plans for a small study to optimize VCN-01 dosing.
2026-04-17 19:39:25
Theriva™ Biologics will present new data and subgroup analyses from its VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic cancer at the AACR 2026 Annual Meeting. The data, including tumor response and biomarker analyses, support an immune-mediated mode of action for VCN-01 and show improved outcomes in various patient subgroups. The company also announced alignment with the FDA and EMA on a proposed pivotal Phase 3 clinical trial for VCN-01 in first-line metastatic PDAC patients.
